This document is from our Archive and no action should be taken in reliance on it without specific legal advice. You can perform a search for more recent content.

Inside Life Sciences

Post

Infliximab: battle of the biosimilars

On 23 May, the CMA issued a statement of objections, which is a provisional finding that Merck Sharp & Dohme Limited (MSD) has breached UK competition law by abusing its dominant position.

Post

Using private prosecutions to tackle counterfeit drugs

As rights holders, the protection of your brand and IP are of paramount importance.

Post

SPC and patent research exemptions consultation: views sought from across industry

A wide-ranging consultation on a 'recalibration' of the EU regime for supplementary protection certificates and patent research exemptions has been launched by the European Commission.

Post

Future of the EMA and medicines regulation in the UK

On 4 December 2017, we are holding a panel discussion at Mishcon de Reya on the future of medicines regulation in the UK post-Brexit.

Post

Health apps: Patient empowerment, but at what cost?

With the NHS increasingly prescribing health apps that assist with the management of particular health conditions, and Health Secretary, Jeremy Hunt, revealing ambitious plans to provide patients with access to their medical records through apps by 2018

Post

Restructuring doesn’t have to be a messy ordeal

A company's decision to restructure can be prompted by a number of different things – it could be as a consequence of success, the result of disagreements, or simply because of commercial imperatives.

Post

Patents Court considers new approach to scope of claims in validity context

In August 2017, the Supreme Court issued its much-anticipated decision in Actavis v Lilly, substantially revising the approach to determining the scope of protection of patent claims in infringement cases, including the role to be played by the doctrine of equivalents.